AzacitidineMyelodysplastic SyndromesAntimetabolites, AntineoplasticLeukemia, Myelomonocytic, ChronicChromatography, Supercritical FluidCompassionate Use TrialsLeukemia, Myeloid, AcuteInjections, SubcutaneousAnemia, RefractoryConsolidation ChemotherapyInduction ChemotherapyAnemia, Refractory, with Excess of BlastsDrug ApprovalDNA MethylationDNA Modification MethylasesTreatment OutcomeSurvivalInternational AgenciesEpigenomicsUnited States Food and Drug AdministrationThalidomideDrug Administration ScheduleAntimetabolitesRemission InductionBiological AvailabilityBlood TransfusionLeukemia, MyeloidTetrazolium SaltsCytarabineAntineoplastic Combined Chemotherapy ProtocolsMaximum Tolerated DoseFatigueAcute DiseaseRetrospective StudiesHematopoietic Stem Cell TransplantationRecurrence